clinical trial · NCT04523727
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
Keryx Biopharmaceuticals·phase3·suspended·n = 45
Hyperphosphatemia Related to Chronic Kidney Diseaseferric citrate
brief summary
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
started
Jun 16, 2022
primary completion
Dec 1, 2026
completion
Oct 1, 2027
last updated
Feb 17, 2026
official title
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol